Business Wire

ASICS

30.3.2022 01:03:11 CEST | Business Wire | Press release

Share
ASICS Experiment Reveals Just One Week of Physical Inactivity Has a Similar Impact as a Week of Broken Sleep on Our State of Mind

Today, the impact of physical inactivity on our mental state has been revealed for the first time in the Mind Racei – an ASICS experiment in which regular exercisers paused their normal fitness routines for one week. The impact on their state of mind was found to be similar to a week of broken sleepii , with participants reporting a 23% increase in racing thoughts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005848/en/

Reassuringly, the results of ASICS’ Uplifting Minds Studyiii , involving thousands of participants from across the globe, proves it can take just 15:09 minutes of physical activity to lift our mental state – even after periods of inactivity.i

The Mind Race: just one week of inactivity significantly lowers our state of mind

Professor Brendon Stubbs, a leading researcher in movement and the mind, monitored the State of Mindiv scores of healthy participantsv who agreed to pause their regular exercise routines for just one week. The results are significant with both their cognitive and emotional wellbeing being impacted. When active people stopped moving, their confidence dropped by 20%; positivity fell by 16%, energy levels slumped by 23% and their ability to cope with stress reduced by 22%.

In fact, after just one week of no exercise, participants’ overall State of Mind score dropped by an average of 18% - decreasing from a high 68 out of 100 when physically active to a mediocre 55 out of 100 when they stopped exercising. The effects of this inactivity are captured in the Mind Race experiment film asics.com/mindrace , following a group of study participants.

Just 15 minutes of activity can uplift our state of mind

But there is good news. Participants were monitored when they returned to their regular exercise regime and all experienced immediate improvements in their state of mind – showing how quickly the negative effects of inactivity can be reversed. Professor Brendon Stubbs also analysed data from thousands of people who participated in ASICS' ongoing Uplifting Minds Study since June 2021. The Study uses cutting edge technology to mimic EEG and capture the impact of exercise on people’s state of mind. Based on data from across sports and across regions, just 15.09 minutes of exercise can significantly impact our mental state.

Commenting on the results, Professor Brendon Stubbs said: “We know that exercise is good for our mental health but the impact of rest and restarting exercise is less clear. Now, thanks to new technology and the contribution of thousands of people, we’ve been able to pinpoint just how much exercise is needed to trigger a positive mental impact. This ASICS study helps to quantify the amount of exercise to improve mental health and make it more tangible. Taking time to rest is very important. This study shows that people’s wellbeing bounces back very quickly after a period of rest when people resume regular exercise again.”

Gary Raucher, EVP, ASICS EMEA said: “Our founding philosophy is literally in our name, Anima Sana In Corpore Sano or a Sound Mind in a Sound Body. And we believe our focus on the benefits of sport and movement, not just on the body, but also on the mind, has never been more relevant. We know the last two years have been tough on the mental state of many. And while not the answer for everyone, we know exercise can make a difference. We hope to inspire more people to move with ASICS, even for just 15.09 minutes to feel the benefits on body and mind.”

To be part of ASICS’ ongoing Uplifting Minds Study and see the impact of exercise on your own State of Mind, visit https://minduplifter.asics.com/

Notes to Editors

Download imagery
Watch video link

For further information, images or to organize an interview with Professor Brendon Stubbs, please contact Asics@Golin.com

ASICS’ Uplifting Minds Study enables people all over the world to measure the impact of movement on their mind. Using cutting edge facial scanning technology and self-reported data, ASICS has measured the impact of exercise on thousands of minds from 79 countries over a 10-month period.

ASICS’ Mind Race, a three-week extension of the study, measured what happened to the minds of 58 regular exercisers from 21 countries when they stopped exercising for just one week. Using self-reported data, qualitative questionnaires and cutting-edge technology, the study pinpointed the effects of both physical activity and inactivity on participants mental wellbeing.

___________

i ASICS’ Mind Race Study 2022
ii Comparison drawn from Soomi Lee, Naturally Occurring Consecutive Sleep Loss and Day-to-Day Trajectories of Affective and Physical Well-Being, Annals of Behavioral Medicine, 2021, DOI: 10.1093/abm/kaab055
iii ASICS’ Uplifting Minds Study 2021-2022
iv ASICS proprietary State of Mind score is a rating out of 100 made up of 10 emotional and cognitive metrics, including: composure, resilience, positivity, contentment, relaxation, confidence, alertness, calmness, focus and energy.
v Volunteers who passed the screening criteria and consented to participate. Screening criteria included: adults (age 18+), already physically active (doing more than 150 minutes of moderate to vigorous exercise per week) and willing to stop exercising for one week with the belief it would not have a detrimental impact on their mental health.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye